Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Liabilities (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Total Liabilities readings, the most recent being $33.4 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 88.75% to $33.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.4 million, a 88.75% increase, with the full-year FY2025 number at $33.4 million, up 88.75% from a year prior.
  • Total Liabilities hit $33.4 million in Q4 2025 for Avalo Therapeutics, roughly flat from $33.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $224.8 million in Q1 2024 to a low of $13.7 million in Q4 2023.
  • Median Total Liabilities over the past 5 years was $38.4 million (2022), compared with a mean of $49.8 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 428.95% in 2024 and later plummeted 92.92% in 2025.
  • Avalo Therapeutics' Total Liabilities stood at $57.1 million in 2021, then decreased by 22.49% to $44.3 million in 2022, then tumbled by 69.09% to $13.7 million in 2023, then rose by 29.3% to $17.7 million in 2024, then surged by 88.75% to $33.4 million in 2025.
  • The last three reported values for Total Liabilities were $33.4 million (Q4 2025), $33.6 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.